Sugi Predict

Sugi Predict / Compounds / SCHEMBL24824751

SCHEMBL24824751

SCHEMBL24824751

COc1c(N)ccc(C)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 6/20 0.40
▸ TUBB4A P04350 2/20 0.39
▸ TUBB P07437 2/20 0.39
▸ TUBA3C P0DPH7 2/20 0.39
▸ TUBA1B P68363 2/20 0.39
▸ TUBA4A P68366 2/20 0.39
▸ TUBB4B P68371 2/20 0.39
▸ TUBB3 Q13509 2/20 0.39
▸ TUBB2A Q13885 2/20 0.39
▸ TUBB8 Q3ZCM7 2/20 0.39
▸ TUBA3E Q6PEY2 2/20 0.39
▸ TUBA1A Q71U36 2/20 0.39
▸ TUBA1C Q9BQE3 2/20 0.39
▸ TUBB6 Q9BUF5 2/20 0.39
▸ TUBB2B Q9BVA1 2/20 0.39
▸ TUBB1 Q9H4B7 2/20 0.39
▸ ALDH1A1 P00352 6/20 0.34
▸ TDP1 Q9NUW8 4/20 0.34
▸ TSHR P16473 2/20 0.34
▸ HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14405259 0.81 ALDH1A1 (0.36) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2426464 0.80 ALDH1A1 (0.39) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL10944142 0.80 TUBB4A (0.42) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL30126262 0.80 TUBB4A (0.42) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL5238486 0.78 IDO1 (0.45) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL28092350 0.78 ALDH1A1 (0.40) CYP3A4ALDH1A1TDP1TSHRHSD17B10
SCHEMBL9410517 0.77 ALDH1A1 (0.45) CYP3A4ALDH1A1TSHRHSD17B10GAA
SCHEMBL5270603 0.77 POLB (0.41) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL10700601 0.77 POLB (0.46) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL22366678 0.77 HTR2C (0.37) CYP3A4TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163004-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2025-05-22 — — US disclosed
US-20240190829-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2024-06-13 — — US disclosed
CN-117794912-A Substituted heterocyclic compounds 百时美施贵宝公司 2024-03-29 — — CN disclosed
EP-4337655-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS Bristol-Myers Squibb Company (US) 2024-03-20 — — EP disclosed
US-11866414-B2 Substituted heterocyclic compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-09 — — US disclosed
US-20220411384-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2022-12-29 — — US disclosed
US-20220411384-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2022-12-29 — — US disclosed
WO-2022241171-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2022-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11866414-B2 Substituted heterocyclic compounds TYK2, JAK2, STAT3 CYP3A4 3160/4885TUBB4A 2458/4885TUBB 1361/4885
US-20250163004-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS TYK2, JAK2, STAT3 CYP3A4 3160/4885TUBB4A 2458/4885TUBB 1361/4885
US-20220411384-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS TYK2, JAK2, STAT3 CYP3A4 3160/4885TUBB4A 2458/4885TUBB 1361/4885
US-20240190829-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS TYK2, JAK2, STAT3 CYP3A4 3160/4885TUBB4A 2458/4885TUBB 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.